The prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) mutations was determined among 95 human immunodeficiency virus-infected Thai children who were treated with dual nucleoside reverse-transcriptase inhibitors. Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal.
The prevalence of nucleoside reverse-transcriptase inhibitor (NRTI) mutations was determined among 95 human immunodeficiency virus-infected Thai children who were treated with dual nucleoside reverse-transcriptase inhibitors. Almost all children had resistance to at least 1 NRTI, and approximately half of the children had resistance to multiple NRTIs. Cross-resistance to stavudine and azidothymidine was universal.
Dual nucleoside reverse-transcriptase inhibitor (NRTI) regimens have been the antiretroviral therapy of choice in many resource-limited countries, including Thailand, until recently, when nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based HAART has become more available. Data from studies of adults infected with HIV clade B and clade A/E and of small cohorts of children infected with HIV clade B or clades A, C, or F have shown that treatment with dual NRTIs does not suppress HIV well, and cross-resistance can occur within the same class of drugs [1] [2] [3] [4] [5] [6] [7] . There is no data on drug resistance in children with HIV clade A/E, which is the predominant clade in Thailand. Resistance data will help to guide the selection of salvage regimens, not only for children who are treated with dual NRTIs, but also when NRTIs are used as part of combination therapy.
Materials and methods. In this cross-sectional study, 100 children were recruited who had been treated with dual NRTIs for at least 6 months and who attended the pediatric infectious diseases clinics at Queen Sirikit National Institute of Child Health ( ) and Chulalongkorn University Hospital n p 90 ( ) from March through May 2003. The institutional n p 10 review board committees of the Thai Ministry of Public Health and Chulalongkorn University approved the study.
For each patient, a complete blood cell count and CD4 cell count were determined, HIV RNA PCR was performed with Roche Amplicor version 1.5 (Roche Diagnostic Systems), and reverse-transcriptase genotypic resistance was assessed by a method validated for HIV clade A/E [8] .
The determination of NRTI mutations was based on the guidelines published by the International AIDS Society-United States (IAS-USA) Drug Resistance Mutation Group [9] , but we did not include E44D/V118I as a nucleoside analogue-resistance mutation (NAM). Therefore, in the present report, a NAM is defined by the presence of any of the following mutations: M41L, D67N, K70R, L210W, T215Y/F, or K219Q/E. In the present report, NRTI resistance is defined by the presence of any mutation that confers resistance to any NRTI. Similarly, resistance to a specific NRTI is defined by the presence of mutations that cause resistance to that particular NRTI. Comparisons of resistance and risk for mutations between dual NRTI regimens were performed with the x 2 test, Fisher's exact test, and univariate logistic regression analysis.
Results. Of 100 enrolled children, 95 fulfilled the enrollment criteria and were included in the analysis. Five children were excluded because they were receiving antiretroviral regimens other than a dual NRTI regimen. The demographic characteristics, HIV disease status, and antiretroviral treatment data for the cohort are shown in table 1. The majority of patients had mild or moderate symptoms and were of normal weight and height. Children with weight and height !2 SD of the reference value for Thai children of the same sex and age group had significantly lower median CD4 cell percentages (10% [IQR, 3%-15%]) but had similar HIV RNA levels, compared with the overall cohort. Most of the children were receiving their first treatment regimen and were treated with azidothymidine and didanosine.
The prevalence of HIV with NRTI resistance is shown in figure 1 . Almost all of the patients had HIV with resistance to 1 or more NRTI. Patients with lamivudine resistance had HIV with 1 or more of the following mutations: M184V ( ), n p 18 M184I ( ), E44D ( ), and V118I ( ). Only 1 n p 4 n p 5 n p 16 patient had HIV with a didanosine-specific mutation (L74V), and this patient was receiving azidothymidine and didanosine. No patients had HIV with multiple-NRTI-resistance 69-inser- tion complex or K65R or V75T mutations, the latter being a signature of stavudine resistance. Forty percent of patients had у4 NAMs.
The comparison of resistance to various NRTIs, by regimen, is shown in figure 2. Regimens that contained azidothymidine and/or stavudine resulted in the emergence of resistance to azidothymidine and stavudine. Regimens that contained lamivudine resulted in the emergence of significantly more resistance to lamivudine and abacavir. Seven children who were receiving didanosine-based regimens had HIV with an 184V/I mutation without ever having received lamivudine. The Q151M multidrug-resistance mutation was seen only in children who were treated with didanosine. There was no difference between NAMs detected in children receiving regimens that included lamivudine and NAMs detected in children receiving regimens that did not include lamivudine.
The risk factors that contribute to the emergence of reversetranscriptase resistance were explored. The HIV RNA level, the CD4 cell percentage and cell count, the duration of treatment with antiretrovirals, the number of antiretrovirals and regimens to which the patient was exposed, and the age and the growth (height and weight) of the patient did not differ between children who had and children who did not have mutations, nor did they confer the risk for the emergence of у4 NAMs.
Discussion. The present study shows that the majority of children who were receiving dual NRTI regimens had HIV with NRTI mutations, and ∼90% had HIV with NAMs, which confer cross-resistance among NRTIs. Infection with HIV with у4 NAMs is associated with resistance to all NRTIs except lamivudine. Forty percent of the children in the present study had HIV with у4 NAMs, and, for these patients, the likelihood of treatment with new NRTIs (except for lamivudine) having adequate viral suppressive effect is low. Among children who were receiving lamivudine-based regimens, mutations conferring lamivudine resistance were very common, further limiting the choice of NRTIs.
Reports have shown high rates of cross-resistance to both azidothymidine and stavudine [4, 8, 10] . Our study confirms other reports that cross-resistance to both azidothymidine and stavudine is almost universal, making the options for salvage therapy more limited if 1 of these 2 drugs had been previously used.
There have been some suggestions that lamivudine can reverse the effect of a mutation that confers azidothymidine resistance, which may explain why relatively few NAMs were detected in children who received regimens that included azidothymidine and lamivudine, compared with NAMs that were detected in children who received other NRTI combinations [5, 8, 11] . We did not see this in the present study. The HIV with M184V mutations seen in lamivudine-naive children was likely the result of exposure to didanosine [6, 12, 13] .
Despite the common use of didanosine-based therapy in the study cohort, only 1 child had HIV with an L74V mutation. This finding is in accordance with those of other reports that show the L74V mutation commonly occurs when didanosine is used alone but not when it is combined with other NRTIs [1, 8, 14] . However, in the children we describe, the high prevalence of HIV with NAMs would confer didanosine resistance. In both the Thai adult cohort [8] and the cohort we describe, HIV with a Q151M multidrug-resistance mutation was seen only in patients who were treated with didanosine, and HIV with the multiple-NRTI-resistance 69-insertion complex was not detected. The HIV mutations seen in the children in our Figure 1 . Prevalence of HIV with nucleoside reverse-transcriptase inhibitor (NRTI) resistance among 95 HIV-infected children who had received dual NRTI therapy for at least 6 months. Any NRTI, mutations that confer resistance to any NRTI; 3TC, lamivudine-resistance mutations (M184V/I, E44D, and V118I); ddI, didanosine-resistance mutation (L74V); Q151M, the Q151M multidrug-resistance mutation; and NAMs, nucleoside analogue-resistance mutations (M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E). Of the patients who had NAMs, 60% had !4 NAMs, and 40% had уNAMs. ), by current dual NRTI n p 95 regimen. Nucleoside analogue-resistance mutations (NAMs) include M41L, D67N, K70R, L210W, T215Y/F, and K219Q/E mutations. AZT, azidothymidineresistance mutations (NAMs); d4T, stavudine-resistance mutations (NAMs); 3TC, lamivudine-resistance mutations (M184V/I, E44D, and V118I); ABC, abacavir-resistance mutations (L74V, Y115F, and M184V); ddc, zalcitabine-resistance mutations (L74V and M184V); ddI, didanosine; and Q151M, the Q151M multidrug-resistance mutation.
cohort were not different from the mutations in patients infected with HIV clades B, A, C, and F [1, 8, 10, 15] . Disease status, growth (height and weight), CD4 cell percentage and cell count, HIV RNA level, and duration and types of NRTI regimens received did not predict the risk for the emergence of HIV with resistance, nor did they predict the degree of resistance.
In the study population, azidothymidine and didanosine was the most commonly used dual NRTI regimen. According to published Thai guidelines, one of the options for salvage therapy would be a regimen of stavudine and lamivudine with an NNRTI or a protease inhibitor [16] . Because the Thai Governmental Pharmaceutical Organization (GPO) has recently produced a generic, fixed-dose combination of stavudine, lamivudine, and nevirapine called GPO-vir, this regimen potentially serves as a prime choice for salvage therapy. In agreement with previously published data, the results of the present study show a high rate of cross-resistance to azidothymidine and stavudine; therefore, combining stavudine, to which there is potential resistance, with drugs that have a low resistance threshold, such as lamivudine and nevirapine, would likely not work for most children. A similar fixed dose of this combination of drugs is available in Africa and India. Because of its higher resistance threshold, a protease inhibitor-based regimen may be a better choice. The affordability of a protease inhibitorbased regimen is helped by price reduction programs, in Africa, and by the production of generic protease inhibitors, in Thailand and India.
However, the present study has limitations. First, the patients were selected on the basis of their attendance during the study period at the clinics staffed by our investigators, and the study cohort may not represent the overall patient population at the 2 institutions. Second, we did not select patients on the basis of treatment-failure criteria. The results of the present study, therefore, may not be relevant for children who are receiving dual NRTIs and who have different demographic characteristics from the children in the study cohort, especially children with a shorter exposure to dual NRTI therapy. Third, most of the children in the present study were receiving azidothymidinedidanosine. Therefore, the comparison of HIV mutations among the children threated with the various dual NRTI regimens has to be interpreted with caution. Fourth, there were very few children who had HIV with no mutations, which resulted in our inability to adequately predict the factors that promote the development of mutations.
Nevertheless, we feel that the present study gives an important message on the high prevalence of HIV with NRTI-resistance mutations in children treated with dual NRTI therapy; therefore, globally, dual NRTI therapy should no longer be used for children. Of special significance are the common occurrence of multi-NRTI resistance and an almost universal cross-resistance to azidothymidine and stavudine. We discourage the use of a regimen of 2 previously unused NRTIs, as the backbone regimen, plus an NNRTI, as salvage therapy for children who had been treated with dual NRTI therapy, unless genotyping and expert consultation are available. The appropriate salvage regimens for children for whom dual NRTI therapy fails need to be further investigated.
